Categories: Health

New site in Lommel, Belgium: Aqua free successfully completes set-up phase with ISO 9001 certification

Lommel / Hamburg, 01/15/2026 – Aqua free, a leading provider of innovative drinking-water hygiene solutions, has successfully moved into its new, state-of-the-art facility in Lommel and has now also obtained ISO 9001 certification for the site. This marks a key milestone in the ongoing development of the new location: processes, responsibilities and quality standards have been audited and confirmed against an internationally recognised benchmark.

The site expansion enables Aqua free to strategically increase capacity in research and development as well as production. The new facility allows the company to respond faster and more flexibly to rising demand for advanced membrane filters and to further strengthen bespoke OEM partnerships with leading customers.

ISO 9001 is recognised worldwide as the standard for quality management. It demonstrates that an organisation systematically controls its operations, manages risks, ensures consistent and repeatable quality, and implements continuous improvement – an important trust anchor for customers and partners.

“Especially at a new site, independent confirmation is crucial,” says Martin Langer, Head of Quality Management at Aqua free. “The certification shows that Lommel operates to clear, effective standards, creating a stable foundation for scalable growth and dependable performance.”

Aqua free will continue to develop the management systems at both sites consistently, with the aim of sustainably strengthening quality, transparency and delivery capability.

About Aqua free GmbH and Aqua free Industries

Aqua free GmbH is one of Europe’s leading manufacturers in the field of water hygiene. Since 1999, the owner-managed company has been setting new standards for drinking-water quality and health protection. With innovative filtration and disinfection solutions, Aqua free helps protect hospitals, care facilities, residential buildings and industry from waterborne infections, reducing Legionella and other microorganisms. Certifications to ISO 9001, ISO 14001 and ISO 13485 underline the company’s quality standards.

Aqua free Industries, also part of the group, specialises in membrane filters and bespoke OEM solutions. The company supports customers across several European countries with comprehensive services, from development through to implementation of individual drinking-water hygiene requirements.

For further information, please visit www.aqua-free.com or contact us at:

Aqua free GmbH

Margaretha Gesler

Head of Marketing & Communication

Tel: +49 170 496 79 85

E-Mail: m.gesler@aqua-free.com

Winsbergring 31

22525 Hamburg

Germany

www.aqua-free.com

GlobeNews Wire

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

7 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

7 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

7 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

7 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

7 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

7 hours ago